Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with...

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Dysglycaemia and coronary artery disease (CAD) are associated with impaired endothelial function and elevated inflammatory markers.
• Statins are known to lower cholesterol and possess pleiotropic effects that may benefit cardiovascular health.

Purpose of the Study:

• To investigate the relative importance of lipid-lowering versus pleiotropic effects of statins on endothelial function and inflammation in patients with dysglycaemia and CAD.
• To compare the effects of high-dose simvastatin versus a combination of ezetimibe and low-dose simvastatin on these markers.

Main Methods:

• A randomized trial involving 39 patients with dysglycaemia and CAD.
• Patients received either high-dose simvastatin (80 mg) or a combination of ezetimibe (10 mg) and low-dose simvastatin (10 mg) for 6 weeks.
• Endothelial function (flow-mediated vasodilatation - FMD), serum lipids, and inflammatory markers (C-reactive protein) were assessed at baseline and follow-up.

Main Results:

• Both treatment groups achieved significant reductions in low-density lipoprotein cholesterol.
• Overall, flow-mediated vasodilatation (FMD) increased, and C-reactive protein levels decreased from baseline to follow-up.
• The magnitude of improvement in FMD and C-reactive protein did not differ significantly between the high-dose simvastatin and the ezetimibe/low-dose simvastatin groups.

Conclusions:

• Lipid lowering, achieved through statin therapy, is the primary driver for improvements in endothelial function and inflammatory markers in patients with dysglycaemia and CAD.
• The pleiotropic effects of statins appear to play a lesser role compared to their lipid-lowering capacity in this patient population.